Kyntra Bio (NASDAQ:KYNB – Get Free Report) and Prothena (NASDAQ:PRTA – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.
Volatility and Risk
Kyntra Bio has a beta of 1.05, suggesting that its stock price is 5% more volatile than the S&P 500. Comparatively, Prothena has a beta of -0.29, suggesting that its stock price is 129% less volatile than the S&P 500.
Analyst Ratings
This is a summary of recent recommendations and price targets for Kyntra Bio and Prothena, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Kyntra Bio | 1 | 1 | 4 | 0 | 2.50 |
| Prothena | 1 | 1 | 5 | 1 | 2.75 |
Profitability
This table compares Kyntra Bio and Prothena’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Kyntra Bio | 2,199.13% | N/A | -47.27% |
| Prothena | -80.68% | -16.45% | -14.51% |
Institutional & Insider Ownership
72.7% of Kyntra Bio shares are held by institutional investors. Comparatively, 97.1% of Prothena shares are held by institutional investors. 4.2% of Kyntra Bio shares are held by company insiders. Comparatively, 10.4% of Prothena shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Earnings and Valuation
This table compares Kyntra Bio and Prothena”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Kyntra Bio | $6.44 million | 3.84 | $183.45 million | $45.30 | 0.13 |
| Prothena | $9.68 million | 47.81 | -$244.09 million | ($0.84) | -10.52 |
Kyntra Bio has higher earnings, but lower revenue than Prothena. Prothena is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.
Summary
Prothena beats Kyntra Bio on 8 of the 15 factors compared between the two stocks.
About Kyntra Bio
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
About Prothena
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer’s disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.
Receive News & Ratings for Kyntra Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kyntra Bio and related companies with MarketBeat.com's FREE daily email newsletter.
